Bicara Therapeutics Inc. filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing bifunctional therapies for solid tumors. Forms 8-K record financial results, business highlights, ficerafusp alfa clinical updates, material definitive agreements and other events, including common stock and pre-funded warrant financing.
The company’s proxy materials cover annual meeting proposals, board-class elections, auditor ratification and governance matters for an emerging growth company. The filings also describe capital-structure actions and formal exhibits tied to press releases, underwriting agreements and shareholder voting matters.
Bicara Therapeutics (BCAX): CEO Form 4 activity. On 10/13/2025 and 10/15/2025, the CEO exercised stock options at $3.7898 per share for 11,445 and 13,289 shares, then sold the same amounts at weighted average prices of $18.9205 and $18.842, respectively. These transactions were executed under a Rule 10b5-1 trading plan adopted on February 12, 2025. Following the trades, the CEO directly owned 309,892 shares. The reported sale prices reflect weighted averages across ranges of $18.73–$19.635 and $18.73–$18.98.
Bicara Therapeutics Inc. Chief Medical Officer David Raben exercised stock options to acquire 22,000 shares of common stock at $3.7898 per share on October 9, 2025, then sold 22,000 shares at $18.45 per share. After these transactions he directly holds 35,497 common shares and continues to hold 128,870 stock options. Footnotes state that a transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025 and describe a vesting schedule for the underlying option grant.
Bicara Therapeutics’ Chief Financial Officer Hyep Ivan exercised stock options for 6,415 shares of common stock at an exercise price of $3.7898 per share on October 9, 2025, and the resulting shares were sold the same day at a weighted-average price of $18.2278 per share in transactions between $18.15 and $18.41. Following these trades, Ivan directly holds 145,355 shares of Bicara common stock. The exercised options are from a grant that vests in sixteen equal quarterly installments beginning August 8, 2023, and the filing notes that a reported transaction was executed under a Rule 10b5-1 trading plan adopted on February 13, 2025.
Bicara Therapeutics, Inc. (BCAX) filing a Form 144 reports a proposed sale of 6,415 common shares through UBS Financial Services on 10/09/2025 with an aggregate market value of $114,764.00. The shares were acquired the same day by exercise of stock options and paid for in cash. The filing also discloses sales by the same person, Ivan Hyep, in the three prior days: 6,514 shares on 10/06/2025 ($118,356.12), 18,244 shares on 10/07/2025 ($332,385.61), and 5,627 shares on 10/08/2025 ($102,456.42), totaling $553,198.15 in gross proceeds. The issuer had 54,562,841 shares outstanding and the proposed transactions are to occur on the NASDAQ.
Bicara Therapeutics (BCAX) filed a Form 144 notice disclosing a proposed sale of 22,000 common shares, acquired the same day by exercising stock options. The broker listed is UBS Financial Services and the shares are to be sold on Nasdaq with an approximate aggregate market value of $405,900. The filing reports 54,562,841 shares outstanding and indicates the proposed sale date as 10/09/2025. No securities were reported sold in the prior three months. The filer attests they are not aware of undisclosed material adverse information and notes exercise payment was made in cash.
Bicara Therapeutics Chief Financial Officer Hyep Ivan reported a series of transactions under a Rule 10b5-1 trading plan dated 02/13/2025. Between 10/06/2025 and 10/08/2025 the reporting person acquired option grants exercisable at $3.7898 and sold common stock in multiple trades. After the reported transactions the reporting person beneficially owned 145,355 shares of common stock.
The filings show three option grant vestings/exercises (total underlying shares: 30,385 across the three dates) with an exercise price of $3.7898 and expiration on 08/08/2033. Sales were executed at weighted average prices reported between approximately $18.15 and $18.36, and the filer offered to provide per-trade details on request.
Ryan Cohlhepp, President and COO and a director of Bicara Therapeutics, Inc. (BCAX), reported multiple stock and option transactions executed pursuant to a Rule 10b5-1 trading plan adopted on 02/12/2025. On 10/06/2025 and 10/07/2025, the reporting person acquired options exercisable at $3.7898 and recorded option-based increases of 24,000 and 8,000 option rights. Offsetting sales were reported across the same dates totaling 50,500 common shares sold at weighted-average prices around $18.06. Following these transactions the reporting person beneficially owned 202,641 shares of common stock. The Form 4 discloses that vesting of the option shares occurs in sixteen quarterly installments following 08/08/2023.
Bicara Therapeutics, Inc. (BCAX) filing a Form 144 discloses a proposed sale of 5,627 common shares with an aggregate market value of $102,242 on 10/08/2025 through UBS Financial Services on NASDAQ. The filing states these shares were acquired the same day, 10/08/2025, by exercise of stock options and paid in cash.
The notice also lists recent sales by the same person: 6,514 shares on 10/06/2025 for $118,356.12 and 18,244 shares on 10/07/2025 for $332,385.61. The filer affirms they do not possess undisclosed material adverse information and includes the standard Rule 10b5-1 representation language where applicable.
Bicara Therapeutics, Inc. (BCAX) filed a Form 144 notice reporting a proposed sale of 18,244 common shares through UBS Financial Services with an aggregate market value of $328,392.00. The filing states the shares were acquired and are to be sold on 10/07/2025 following an exercise of stock options, with payment in cash.
The notice also discloses a prior sale by the same person: 6,514 shares sold on 10/06/2025 for gross proceeds of $118,356.12. The filer certifies no undisclosed material adverse information and acknowledges Rule 10b5-1/insider-trading attestation language on the form.
Bicara Therapeutics (BCAX) filed a Form 144 disclosing a proposed sale of 10,900 common shares through UBS Financial Services on 10/07/2025 with an aggregate market value of $196,200. The filing lists total outstanding shares of 54,562,841, indicating the sale represents a very small fraction of the company.
The securities were acquired in two non‑qualified option-related transactions: 2,900 shares on 05/12/2024 and 8,000 shares on 10/06/2025, both paid in cash to the issuer. The filer also reported prior sales of 39,600 shares on 10/06/2025 producing gross proceeds of $714,997.10. By signing, the seller represents they have no undisclosed material information.